PERSPECTIVE THERAPEUTICS, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
PERSPECTIVE THERAPEUTICS, INC. (CATX) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $177.90 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $177.90M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $177.10M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $6.00M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $177.90M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $177.10M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $6.00M 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |